UnitedHealth Group Inc vs Viatris Inc — how do they compare? UnitedHealth Group Inc trades at $436 (market cap $382.83B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: UnitedHealth Group Inc is far larger — about 19.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| UNH | VTRS | |
|---|---|---|
Market Cap | $382.83B | $19.79B |
Sector | Health | Health |
52-Week High | $431.68 | $17.39 |
52-Week Low | $237.77 | $8.74 |
Enterprise Value | $429.52B | $32.00B |
Dividend Yield | 2.2% | 2.83% |
Signals from Pluang's Aura AI — not financial advice
UnitedHealth Group (UNH) trades at $426.09, up 0.64% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $6.38 surpassing expectations of $4.94. Revenue growth remains robust, reaching $447.57 billion in 2025, though net margins have compressed to 2.68%. Recent corporate actions include a $2.32 dividend and ongoing share repurchases, while news highlights operational streamlining like reduced pediatric prior authorizations.
UNH's outlook is positive, driven by aging demographics and tech innovation in healthcare, offering upside to the $467.12 consensus target. Risks include regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. Institutional sentiment is strongly bullish, with 82.69% of analysts rating it a buy, supporting long-term growth prospects amid sector tailwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →